

Part VI: Summary of the Risk Management Plan

Summary of risk management plan for Sugammadex Glenmark (sugammadex)

This is a summary of the risk management plan (RMP) for Sugammadex Glenmark. The RMP details important risks of Sugammadex Glenmark, how these risks can be minimised, and how more information will be obtained about Sugammadex Glenmark risks and uncertainties (missing information).

Sugammadex Glenmark summary of product characteristics (SmPC) and its package leaflet (PL) give essential information to healthcare professionals and patients on how Sugammadex Glenmark should be used.

I. The medicine and what it is used for

Sugammadex Glenmark is authorised for:

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

It contains sugammadex as the active substance and it is administered intravenously as a single bolus injection. The bolus injection should be given rapidly, within 10 seconds, into an existing intravenous line

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Sugammadex Glenmark together with measures to minimise such risks and the proposed studies for learning more about Sugammadex Glenmark are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A. List of important risks and missing information

Important risks of Sugammadex Glenmark are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of sugammadex Glenmark. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not

been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of Important Risks and Missing Information	
Important identified risk(s)	• None
Important potential risk(s)	• None
Missing information	• None

II.B. Summary of important risk

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C. Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of sugammadex Glenmark.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Sugammadex Glenmark.